Results demonstrated that only two protein analytes, eotaxin-1 and eotaxin-2, were significantly upregulated following treatment with benralizumab in both asthma and chronic obstructive pulmonary disease (COPD), with higher levels in eosinophil-high patients than in eosinophil-low patients in both studies. This evidence concerns the gene CCL11 and chronic obstructive pulmonary disease.